Avastin is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). With the initial approval in the United States for advanced colorectal cancer in 2004, Avastin became the first anti-angiogenic therapy made widely available for the treatment of patients with an advanced cancer.

Today, Avastin is approved in Europe for the treatment of advanced stages of breast, colorectal, non-small cell lung, kidney, ovarian and cervical cancers. It is available in the United States for the treatment of colorectal, non-small cell lung, kidney, cervical, and recurrent platinum-resistant and platinum-sensitive ovarian cancers, as well as recurrent glioblastoma. In addition, Avastin is approved over 130 other countries worldwide for the treatment of patients with progressive glioblastoma following prior therapy. Avastin is approved in Japan for the treatment of the advanced stages of colorectal cancer, non-small cell lung cancer, breast cancer, ovarian cancer and malignant glioma, including newly diagnosed glioblastoma.